ADD background on T cells at large

This commit is contained in:
Nathan Dwarshuis 2021-08-01 21:52:19 -04:00
parent 8f7ee97f0a
commit 054f6104eb
1 changed files with 78 additions and 8 deletions

View File

@ -61,6 +61,8 @@
\renewcommand{\glossarysection}[2][]{} % remove glossary title
\makeglossaries
\newacronym{til}{TIL}{tumor infiltrating lymphocyte}
\newacronym{tcr}{TCR}{T cell receptor}
\newacronym{act}{ACT}{adoptive cell therapies}
\newacronym{qc}{QC}{quality control}
\newacronym{tcm}{T\textsubscript{cm}}{central memory T cell}
@ -76,6 +78,7 @@
\newacronym{gmp}{GMP}{Good Manufacturing Practices}
\newacronym{cho}{CHO}{Chinese hamster ovary}
\newacronym{all}{ALL}{acute lymphoblastic leukemia}
\newacronym{cll}{CLL}{chronic lymphoblastic leukemia}
\newacronym{pdms}{PDMS}{polydimethylsiloxane}
\newacronym{dc}{DC}{dendritic cell}
\newacronym{il}{IL}{interleukin}
@ -113,7 +116,6 @@
\newacronym{bmi}{BMI}{body mass index}
\newacronym{a2b1}{A2B1}{integrin $\upalpha$1$\upbeta$1}
\newacronym{a2b2}{A2B2}{integrin $\upalpha$1$\upbeta$2}
\newacronym{til}{TIL}{tumor infiltrating lymphocytes}
\newacronym{nsg}{NSG}{NOD scid gamma}
\newacronym{colb}{COL-B}{collagenase B}
\newacronym{cold}{COL-D}{collagenase D}
@ -631,15 +633,75 @@ However, the characteristic shared by all the cell types in this application is
the fact that they are adherent. In this work, we explore the use of
microcarrier for T cells, which are naturally non-adherent.
\subsection{overview of T cells in immunotherapies}
% all numbers reflect the citation index in my review paper
One of the first successful T cell-based immunotherapies against cancer is
\glspl{til} [78]. This method works by taking tumor specimens from a patient,
allowing the tumor-reactive lymphocytes to expand \exvivo{}, and then
administered back to the patient along with a high dose of \il{2} [44]. In
particular, \gls{til} therapy has shown robust results in treating melanoma [1],
although \gls{til} have been found in other solid tumors such as
gastointestinal, cervical, lung, and ovarian [78-83], and their presence is
generally associate with favorable outcomes [84]. \glspl{til} are heterogenous
cell mixtures and generally are comprised of CD3 T cells and $\upgamma\updelta$
T cells [85, 86]. To date, there are over 250 open clinical trials using
\glspl{til}.
Besides \gls{til}, the other broad class of T cell immunotherapies that has
achieved great success in treating cancer in recent decades are gene-modified T
cells. Rather than expand T cells that are present natively (as is the case with
\gls{til} therapy), gene-modified T cell therapies entail extracting T cells
from either the cancer patient (autologous) or a healthy donor (allogeneic) and
reprogramming them genetically to target a tumor antigen. In theory this offers
much more flexibility.
T cells with transduced \glspl{tcr} were first designed to overcome the
limitations of \gls{til} [78,79]. In this case, T cells are transduced \exvivo{}
with a lentiviral vector to express a \gls{tcr} targeting a tumor antigen. T
cells transduced with \glspl{tcr} against MART-1 have shown robust results in
melanoma patients [9], and analogous therapies targeted toward MY-ESO-1 have
shown robust results against synovial sarcoma [10]. To date, there are over 200
clinical trials using T cells with transduced \glspl{tcr}.
While transduced \glspl{tcr} offer some flexibility in retargeting T cells
toward relevant tumor antigens, they are still limited in that they can only
target antigens that are presented via \gls{mhc} complexes. \gls{car} T cells
overcome this limitation by using a the heavy and light chains (scFv) from a
\gls{mab} which can target any antigen recognizable by antibodies. \gls{car} T
cells were first demonstrated in 1989, where the author swapped the
antigen-recognition domains of a native \gls{tcr} with a that of a foreign
\gls{tcr} [91]. Since then, this method has progressed to using an scFv with a
CD3$\upzeta$ stimulatory domain along with the CD28, OX-40, or 4-1BB domains for
costimulation. Since these can all be expressed with one protein sequence,
\gls{car} T cells are relatively simple to produce and require only a single
genetic transduction step (usually a lentiviral vector) to reprogram a batch T
cells \exvivo{} toward the desired antigen. \gls{car} T cells have primarily
found success in against CD19- and CD20-expressing tumors such as \gls{all} and
\gls{cll} (eg B-cell malignancies).
% BACKGROUND where else have they been approved?
Out of all the T cell therapies discussed thus far, \gls{car} T cells have
experienced the most commercial success and excitement. In 2017, Novartis and
Kite Pharma acquired FDA approval for \textit{Kymriah} and \textit{Yescarta}
respectively, both of which are \gls{car} T cell therapies against B-cell
malignancies.
% BACKGROUND beef this up, this is a big deal
\gls{car} T cells are under further exploration for use in many other tumors,
including multiple myeloma, mesothelioma, pancreatic cancer, glioblastoma,
neuroblastoma, and prostate cancer, breast cancer, non-small-cell lung cancer,
and others [78,79,94,95]. To date, there are almost 1000 clinical trials using
\gls{car} T cells.
% TODO there are other T cells like virus-specific T cells and gd T cells, not
% that they matter...
\subsection*{current T cell manufacturing technologies}
\Gls{car} T cell therapy has received great interest from both academia and
industry due to its potential to treat cancer and other
diseases\cite{Fesnak2016, Rosenberg2015}. In 2017, Novartis and Kite Pharma
acquired FDA approval for \textit{Kymriah} and \textit{Yescarta} respectively,
two \gls{car} T cell therapies against B cell malignancies. Despite these
successes, \gls{car} T cell therapies are constrained by an expensive and
difficult-to-scale manufacturing process\cite{Roddie2019, Dwarshuis2017}.
Despite these success of T cell therapies (especially \gls{car} T cell
therapies) they are constrained by an expensive and difficult-to-scale
manufacturing process\cite{Roddie2019, Dwarshuis2017}.
Of critical concern, state-of-the-art manufacturing techniques focus only on
Signal 1 and Signal 2-based activation via \acd{3} and \acd{28} \glspl{mab},
@ -683,6 +745,14 @@ cytokine release properties and ability to resist exhaustion\cite{Wang2018,
Yang2017}, and no method exists to preferentially expand the CD4 population
compared to state-of-the-art systems.
\subsection{methods to scale T cells}
\subsection{overview of T cell quality}
% memory
% CD4
% viability
\subsection*{integrins and T cell signaling}
Because the microcarriers used in this work are derived from collagen, one key